MARKET

BDSI

BDSI

BDSI
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.485
+0.045
+1.01%
Closed 16:01 07/06 EDT
OPEN
4.520
PREV CLOSE
4.440
HIGH
4.580
LOW
4.420
VOLUME
1.33M
TURNOVER
--
52 WEEK HIGH
7.21
52 WEEK LOW
2.850
MARKET CAP
449.24M
P/E (TTM)
-49.3399
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BDSI stock price target is 8.04 with a high estimate of 9.25 and a low estimate of 6.00.

EPS

BDSI News

More
Hedge Funds Have Never Been This Bullish On BioDelivery Sciences International, Inc. (BDSI)
Insider Monkey · 06/10 22:44
Edited Transcript of BDSI earnings conference call or presentation 7-May-20 8:30pm GMT
Thomson Reuters StreetEvents · 06/10 04:38
Why Is BioDelivery (BDSI) Down 0.4% Since Last Earnings Report?
Zacks · 06/06 16:31
BioDelivery Sciences (BDSI) Presents At Jefferies Healthcare Conference - Slideshow
Seeking Alpha - Article · 06/03 22:11
BioDelivery Sciences to Present at Two Upcoming Investor Conferences
GlobeNewswire · 05/29 17:17
Baker Brothers Snap Up These 3 Biotech Stocks
TipRanks · 05/26 15:43
BioDelivery Sciences Names Jeff Bailey Interim CEO
Benzinga · 05/11 12:52
BioDelivery Sciences Appoints Jeff Bailey Interim CEO
RALEIGH, N.C., May 11, 2020 -- BioDelivery Sciences International, Inc (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with.
GlobeNewswire · 05/11 12:30

Industry

Pharmaceuticals
+0.74%
Pharmaceuticals & Medical Research
+0.72%

Hot Stocks

Symbol
Price
%Change

About BDSI

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.
More

Webull offers kinds of BioDelivery Sciences International, Inc. stock information, including NASDAQ:BDSI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BDSI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BDSI stock methods without spending real money on the virtual paper trading platform.